Captrust Financial Advisors Sorrento Therapeutics, Inc. Transaction History

Captrust Financial Advisors

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 16, 2022	BUY	$1.51 - $2.88 $43,041 - $82,091	28,504 Added 1299.77%	30,697 $48,000
Q2 2022 Aug 23, 2022	SELL	$1.24 - $2.33 $2,790 - $5,242	-2,250 Reduced 50.64%	2,193 $4,000
Q2 2022 Aug 16, 2022	BUY	$1.24 - $2.33 $1,877 - $3,527	1,514 Added 51.69%	4,443 $9,000
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $1,472 - $3,606	736 Added 33.56%	2,929 $7,000
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.23 $4,217 - $6,557	-907 Reduced 29.26%	2,193 $10,000
Q2 2021 Aug 16, 2021	BUY	$6.35 - $10.0 $5,264 - $8,290	829 Added 36.5%	3,100 $30,000
Q1 2021 May 17, 2021	SELL	$7.03 - $16.51 $42,292 - $99,324	-6,016 Reduced 72.6%	2,271 $19,000
Q4 2020 Feb 16, 2021	BUY	$5.76 - $11.95 $10,080 - $20,912	1,750 Added 26.77%	8,287 $57,000
Q3 2020 Nov 17, 2020	BUY	$6.17 - $18.82 $30,152 - $91,973	4,887 Added 296.18%	6,537 $70,000
Q2 2020 Aug 14, 2020	BUY	$1.73 - $6.76 $2,854 - $11,154	1,650 New	1,650 $11,000
Q4 2019 Feb 14, 2020	SELL	$1.45 - $4.17 $2,900 - $8,340	-2,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.86 - $5.94 $3,720 - $11,880	2,000 New	2,000 $10,000

5.47M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.